Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Weak Earnings And Terminated Partnerships, Oh My! Tuesday’s Hottest Stocks

Page 1 of 2

Unilife Corp (NASDAQ:UNIS) and Anthera Pharmaceuticals Inc (NASDAQ:ANTH) were among the stocks losing ground early this morning, though one of them has quickly rebounded to turn that frown upside down. The devil is in the details, so let’s dig into the details which have lead these companies to being actively-traded and scrutinized.

Most Affordable Medical Schools in Europe

Unilife Corp is fading fast after its fourth quarter and full year fiscal 2015 financial results were released after the close of trading yesterday, falling by 9.09% this morning. The drug delivery system company reported revenues of $3.5 million for the fiscal fourth quarter ending on June 30, along with a net loss of $0.22 per share, representing a decline of 47.2% in its revenue and a 46.70% drop in its EPS on a year-over-year basis. Analysts were expecting a loss of $0.16 per share for the quarter. Additionally, Unilife Corp (NASDAQ:UNIS) reported revenues of $13.2 million for the full fiscal year 2015, a decline of 10.20% compared to fiscal year 2014, while its annual loss came in 37.30% higher at $0.81 per share.

The manufacturer of medical products has faced pressure from its shareholders to create more shareholder value in the past couple of months, suggesting the firm hire an advisor to help accomplish the task. The management of Unilife Corp addressed the issue by announcing Morgan Stanley & Co LLC as its new strategic advisor. According to the official announcement from the medical company, Unilife Corp will seek out “a possible sale of the Company, a strategic partnership with one or more parties or the licensing of some of the Company’s proprietary technologies.

Investors have been very bearish on Unilife in 2015, with its stock declining by 60.83% year-to-date. However, the hedge funds that we track at Insider Monkey were slightly bullish outlook during the quarter ending June 30, perhaps finding an entry point amid the declines. The shares of Unilife Corp (NASDAQ:UNIS) dropped by 46.38% during the second quarter, but the aggregate holdings of the funds we track fell by just 40.35% to $8.38 million during that time, showing that hedge funds collectively added some shares to their portfolios, while ownership remained the same at eight funds. Israel Englander’s Millennium Management was the largest shareholder of the company in our database, owning 1.40 million shares valued at $3.01 million. Broadfin Capital and Raging Capital Management were its other major shareholders, having 1.15 million sharesand 714,820 shares, respectively.

Let’s take a step back and analyze how tracking hedge funds can help an everyday investor. Through our research we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith (and money) in large-cap stocks. In forward tests since August 2012 these top small-cap stocks beat the market by an impressive 60 percentage points, returning 118% (read the details here). Follow the smart money into only their best investment ideas all while avoiding their high fees.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!